We are live on ! Find out more
TCM

TCG Crossover Management Portfolio holdings

AUM $4.16B
1-Year Est. Return 983.43%
This Fund
S&P 500
This Quarter Est. Return
+32.25%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$610M
AUM Growth
+$96.8M
Cap. Flow
-$39.5M
Cap. Flow %
-6.48%
Top 10 Hldgs %
80.69%
Holding
24
New
2
Increased
4
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
ICVX
Icosavax, Inc. Common Stock
ICVX
+$29.6M
2
COGT icon
Cogent Biosciences
COGT
+$22.9M
3
JBIO
Jade Biosciences
JBIO
+$20.5M
4
GERN icon
Geron
GERN
+$16.6M
5
ANTX icon
AN2 Therapeutics
ANTX
+$9.27M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$95M
2
CBAY
Cymabay Therapeutics
CBAY
+$26.6M
3
VRDN icon
Viridian Therapeutics
VRDN
+$16.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
1
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$96.3M 15.8%
2,448,829
-2,692,289
-52% -$95M
GERN icon
2
Geron
GERN
$970M
$75.7M 12.42%
23,589,779
+5,824,566
+33% +$16.6M
COGT icon
3
Cogent Biosciences
COGT
$6.02B
$66.7M 10.93%
5,631,042
+2,000,000
+55% +$22.9M
VECT
4
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$52.9M 8.68%
3,113,600
– –
JBIO
5
Jade Biosciences
JBIO
$1.33B
$37.8M 6.19%
62,894
+32,000
+104% +$20.5M
ICVX
6
DELISTED
Icosavax, Inc. Common Stock
ICVX
$36.8M 6.03%
+3,703,704
New +$29.6M
MDGL icon
7
Madrigal Pharmaceuticals
MDGL
$12.3B
$34.6M 5.68%
149,917
– –
TYRA icon
8
Tyra Biosciences
TYRA
$1.49B
$33.9M 5.56%
1,989,103
– –
KALV
9
DELISTED
KalVista Pharmaceuticals
KALV
$30.6M 5.01%
3,395,495
– –
VTYX
10
DELISTED
Ventyx Biosciences
VTYX
$26.8M 4.39%
815,724
– –
DYN icon
11
Dyne Therapeutics
DYN
$4.68B
$18.6M 3.04%
1,650,150
– –
KURA icon
12
Kura Oncology
KURA
$1.13B
$15.1M 2.47%
1,423,642
– –
GPCR icon
13
Structure Therapeutics
GPCR
$3.38B
$14.5M 2.39%
350,000
– –
IMVT icon
14
Immunovant
IMVT
$8.51B
$12.4M 2.04%
654,853
– –
SLN
15
Silence Therapeutics
SLN
$834M
$11.6M 1.9%
2,104,875
– –
ANTX icon
16
AN2 Therapeutics
ANTX
$211M
$11M 1.8%
+1,289,320
New +$9.27M
TRDA icon
17
Entrada Therapeutics
TRDA
$273M
$8.86M 1.45%
584,955
– –
MRUS
18
DELISTED
Merus
MRUS
$7.9M 1.3%
300,000
– –
CABA icon
19
Cabaletta Bio
CABA
$529M
$6.28M 1.03%
486,795
– –
ACRS icon
20
Aclaris Therapeutics
ACRS
$885M
$5.49M 0.9%
529,839
– –
CCCC icon
21
C4 Therapeutics
CCCC
$474M
$3.51M 0.58%
1,276,574
+26,574
+2% +$85.4K
ALPN
22
DELISTED
Alpine Immune Sciences Inc
ALPN
$2.6M 0.43%
253,069
– –
VRDN icon
23
Viridian Therapeutics
VRDN
$2.61B
– –
-663,610
Closed -$16.9M
CBAY
24
DELISTED
Cymabay Therapeutics
CBAY
– –
-3,048,257
Closed -$26.6M

Similar funds

GCM
Gates Capital Management New York $4.16B AUM 21% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
CIC
Chilton Investment Company Stamford, Connecticut $4.17B AUM 1.75% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $4.15B AUM 31.06% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $4.15B AUM
CAM
Crake Asset Management London, United Kingdom $4.18B AUM 13.97% 1-Year Est. Return
JFG
JMG Financial Group Downers Grove, Illinois $4.14B AUM 21.49% 1-Year Est. Return

TCG Crossover Management's Q2 2023 Portfolio in Review

As of Q2 2023, TCG Crossover Management held 24 positions worth $610M, up 19% from $513M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

TCG Crossover Management withdrew a net $39.5M in Q2 2023, closing 2 positions and reducing 1 holding. Its most notable exit was Cymabay Therapeutics, an estimated $26.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, TCG Crossover Management opened a new position in Icosavax, Inc. Common Stock worth $36.8M.

  • TCG Crossover Management's largest Q2 2023 buy was Icosavax, Inc. Common Stock: 3,703,704 shares worth $36.8M.
  • TCG Crossover Management added most to Cogent Biosciences in Q2 2023, an estimated $22.9M increase.
  • TCG Crossover Management's biggest Q2 2023 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $95M.
  • TCG Crossover Management fully exited Cymabay Therapeutics in Q2 2023, selling an estimated $26.6M.
  • TCG Crossover Management's ten largest holdings make up 81% of its $610M portfolio in Q2 2023.
  • TCG Crossover Management opened 2 new positions and closed 2 in Q2 2023.
  • TCG Crossover Management's portfolio value rose 19% quarter-over-quarter to $610M.

Based on TCG Crossover Management's 13F filing for Q2 2023, filed 14 Aug 2023.